April 3
HERZLIYA PITUACH, Israel, April 3, 2011 - SMT Research and Development Ltd.
NEW ORLEANS, April 3, 2011 - A pooled analysis of the SPIRIT II, III, IV and COMPARE trials presented
today further reinforces the positive clinical performance of Abbott's (NYSE:
ABT) market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System.
DUBAI, UAE, April 3, 2011 - As GCC countries approach their stiflingly hot summer months, the matter
of cooling people, places and businesses will be at the forefront of
everybody's mind.
NEW ORLEANS, April 3, 2011 - Abbott (NYSE: ABT) today announced positive one-year results from 101
patients enrolled in the second phase of the ABSORB trial evaluating the
world's first drug eluting Bioresorbable Vascular Scaffold (BVS) for the
treatment of coronary artery disease.
VENLO, Netherlands and MELBOURNE, Australia, April 3, 2011 - -- QIAGEN to acquire Cellestis Limited (CST:AU) via a Scheme of
Arrangement (the Scheme) for approximately A$341 million(1) (US$355 million),
or A$3.55 per share
-- Unanimous support from Cellestis board of directors(2); QIAGEN granted
options to acquire up to 19.9% of Cellestis ordinary shares under certain
circumstances, subject to regulatory approvals
-- Acquisition provides QIAGEN with exclusive access to QuantiFERON(R)
technology for high sensitivity, early disease detection not possible with
other diagnostic approaches
-- QuantiFERON(R) technology successfully commercialized with two
marketed Cellestis tests for detection of latent tuberculosis (TB) and
life-threatening CMV virus
-- QIAGEN to expand QuantiFERON(R) portfolio, migrate technology to
QIAsymphony and QIAensemble platforms and leverage synergies with current
QIAGEN assay portfolio and pipeline
-- Acquisition would accelerate QIAGEN's sales and adjusted EPS growth
rates in 2012
QIAGEN N.V.
